From: Ideal marker for targeted axillary dissection (IMTAD): a prospective multicentre trial
SLN | TLN | |
---|---|---|
Negative | 31 (68.9%) | 23 (51.1%) |
ITC | 1 (2.2%) | 1 (2.2%) |
Micrometastasis | 2 (4.4%) | 6 (13.3%) |
Macrometastasis | 11 (24.4%) | 15 (33.3%) |
False-negative | 8 (4 micrometastasis, 4 macrometastasis) | 0 |
True-positive | 13 | 21 |
False-negativity rate for micrometastasis and macrometastasis (from the ypN + subcohort, n = 83) | 9.6% | 0.0% |
False-negativity rate for macrometastasis only (from the ypN + subcohort, n = 83) | 4.8% | 0.0% |
Total | 45 (100%) | 45 (100%) |